# Significant Associations betweenChlamydia trachomatis and Neisseria gonorrhoeae Infections in Human Immunodeficiency Virus-Infected Pregnant Women

Authors: Bongekile Ngobese; Khine Swe Swe-Han; Partson Tinarwo; Nathlee S. Abbai
Journal: Infectious Diseases in Obstetrics and Gynecology
 (2022)

---

## Abstract

There is a lack of data on the burden ofChlamydia trachomatis and Neisseria gonorrhoeae among human immunodeficiency virus- (HIV-) infected pregnant women in South Africa. We conducted a cross-sectional study which included 385 HIV-infected pregnant women attending antenatal clinic at the King Edward VIII Hospital in Durban, South Africa. The women provided vaginal swabs which were tested for C. trachomatis and N. gonorrhoeae. The prevalence of the individual STIs was as follows: C. trachomatis (47/385, 12.2%) and N. gonorrhoeae (16/385, 4.1%). Having a circumcised partner, testing positive for N. gonorrhoeae, and perceiving themselves of being at risk for infection were shown to increase the risk for C. trachomatis infection. Without controlling for the other factors, testing positive for N. gonorrhoeae increased the risk for C. trachomatis infection by 10-fold (OR: 10.17, 95% CI: 3.39-29.66, p<0.001). Similarly, adjusting for the other factors, the risk for C. trachomatis infection in women who tested positive for N. gonorrhoeae was 9-fold (OR: 9.16, 95% CI: 2.19-40.18, p=0.003). The following factors were associated with the increased risk of N. gonorrhoeae infection: not knowing their partner’s HIV status, partner having other partners, and C. trachomatis infection status. Without controlling for the other factors, testing positive for C. trachomatis increased the risk for N. gonorrhoeae infection by 6-fold (OR: 6.52, 95% CI: 2.22-18.49, p<0.001). Similarly, adjusting for the other factors, the risk for N. gonorrhoeae infection in women who tested positive for C. trachomatis was 6-fold (OR: 6.09, 95% CI: 1.73-22.03, p=0.005). We found a significant association between C. trachomatis and N. gonorrhoeae in the pregnant women and the risk factors associated with these pathogens. Future studies are urgently required to investigate the impact of C. trachomatis/N. gonorrhoeae coinfections in HIV pregnant women since this data is lacking in our setting. In addition, etiological screening of C. trachomatis and N. gonorrhoeae during antenatal clinic is urgently required to prevent adverse pregnancy and birth outcomes associated with these infections.


---

## Body

## 1. Introduction

Chlamydia trachomatis (C. trachomatis) and Neisseria gonorrhoeae (N. gonorrhoeae) are the most commonly reported bacterial sexually transmitted infections (STIs) in humans worldwide, with an estimated 131 million new cases of chlamydia and 78 millions of gonorrhoea among adults in 2016 [1]. In the African region, C. trachomatis and N. gonorrhoeae account for 12 and 11.4 million new cases per year, respectively [1, 2]. The majority of new STIs occur among women aged between 15 and 49 years old [3]. South Africa has one of the highest prevalence rates of human immunodeficiency virus (HIV) and STIs, with prevalence and incidence rates higher than other African countries [4, 5]. KwaZulu-Natal (KZN), one of South Africa’s most densely populated provinces, has been reported to be significantly affected by both HIV and STIs particularly among pregnant and nonpregnant young women [6]. However, the prevalence of STIs has not been well documented to date especially in HIV-infected pregnant women.In Africa, STIs are a major cause of maternal and perinatal morbidity among HIV-infected pregnant women and are associated with adverse pregnancy and birth outcomes [7–9]. In most cases, C. trachomatis and N. gonorrhoeae infections are asymptomatic especially in pregnant women [10, 11]. According to the World Health Organization (WHO), approximately in 60% to 80% of cases, infection with C. trachomatis does not manifest symptoms and remains asymptomatic [1]. Similarly, studies have reported that 50% to 80% of women infected with C. trachomatis do not develop symptoms, and these women are considered silent reservoirs of the pathogen and continue to transmit it sexually [12]. Moreover, physiological changes during pregnancy such as changes in vaginal discharge and urinary habits may further mask the signs and symptoms of true infection [13].C. trachomatis and N. gonorrhoeae are significant etiological agents of cervicitis, accounting for up to 50% of cases [14]. If left untreated, it can cause a variety of adverse effects and complications, such as pelvic inflammatory disease, miscarriage, premature rupture of membranes, low birth weight, and preterm labour and delivery [15–17]. During labour, these infections can be transmitted vertically from pregnant women to their newborns [18, 19]. Studies have shown that the risk of the adverse events in pregnancy and neonates is increased when coinfections with these two organisms are present [15]. Infection with C. trachomatis can lead to neonatal ophthalmia neonatorum and pneumonia, while infection with N. gonorrhoeae can cause neonatal ophthalmia neonatorum and blindness [20, 21]. Several studies have reported that risk factors associated with C. trachomatis and N. gonorrhoeae include younger age, condomless sex, being unmarried, having more than one sexual partner, being unemployed, low level education attainment, frequent alcohol use, frequent tobacco use, illegal substance use, and a history of STIs [11, 22, 23].Coinfection with HIV andC. trachomatis or N. gonorrhoeae is associated with an increased risk of mother-to-child transmission of HIV [7]. To date in KZN, South Africa, there is limited recent data on the prevalence, coinfection rates, and risk factors for curable STIs in HIV-infected pregnant women. In this study, HIV-infected pregnant women were tested for the presence of C. trachomatis and N. gonorrhoeae. This study also assessed the actual risk versus perceived risk of contracting these STIs in the studied population.


## 2. Methods

### 2.1. Ethical Statement

Ethics approval for this study (BREC/00001382/2020) was obtained from the Biomedical Research Ethics Committee (BREC), University of KZN.


### 2.2. Study Population

This was a cross-sectional study among pregnant women, attending the antenatal clinic (ANC) at the King Edward VIII Hospital in Durban, South Africa. At the clinic, women were educated on the consequences of STIs during pregnancy and provided with information on risk reduction for STIs. The clinic attends to 80 to 100 women on a daily basis, and the recruitment for this study took place between October 2020 and April 2021. Women were enrolled in this study if they were HIV infected, 18 years and older, willing to provide written informed consent, willing to provide vaginal swab samples, and willing to provide sociodemographic, behavioral, and clinical data. Patients were explained the process of self-sample collection. Each enrolled women provided self-collected vaginal swabs (dry swabs) for detection of the vaginal infections. The consenting women had also completed a questionnaire on sociodemographic, behavioral, and clinical factors.


### 2.3. Laboratory Procedures

#### 2.3.1. Sample Processing

After collection, the dry swabs were placed in 2 ml of phosphate buffered saline (PBS). The solution was vortexed to dislodge the cells from the swabs, and the swab was discarded. The remaining suspension was centrifuged at 14,000 rpm for 10 mins, and the supernatant was discarded. Recovered pellets were then subjected to further molecular analysis.


#### 2.3.2. DNA Extraction

DNA extraction was performed on the vaginal fluid pellets using the PureLink Microbiome Kit (Thermo Fisher Scientific, United States), according to the manufacturer’s instructions. Briefly, 2 ml of the vaginal fluid samples was centrifuged for 30 minutes at14000×g. The supernatant was discarded, and 800 μl of S1 lysis buffer was added to the pellet and pipetted up and down to mix the sample. The sample was then transferred to the bead tube, and 100 μl of S2 lysis enhancer was added to the bead tube, capped, and vortexed briefly. This was incubated at 95°C for 10 minutes, followed by vortexing at a maximum speed for 7 minutes and further centrifuged at 14000×g for 1 minute. Thereafter, 500 μl of the supernatant was transferred to a clean microcentrifuge tube, avoiding the bead pellet and any cell debris. To bind DNA to the column, 900 μl of binding buffer was added and vortexed briefly. Following this, 700 μl of the sample mixture was loaded onto a spin column-tube and centrifuged at 14000×g for 1 minute. The flow through was discarded, and the spin column was centrifuged at 14000×g for 30 seconds. The spin column was placed in a clean tube; 50 μl of S6 elution buffer was added, and the tube was incubated at room temperature for 1 minute. After 1 minute, the spin column was centrifuged at 14000×g for 1 minute, and the column was discarded, and the purified DNA was stored at -20°C. The concentration of extracted DNA was determined using the NanoDrop spectrophotometer (Thermo Fisher Scientific, United States). DNA samples were stored at –20°C until further molecular analysis. The molecular assays were conducted at the School of Clinical Medicine’s Research Laboratory at the University of KZN.


### 2.4. Detection of STI Pathogens

PCR amplification was performed on the Quant Studio 5 real-time PCR detection system (Thermo Fisher Scientific, Waltham, Massachusetts, United States of America), in a 96-well microtiter reaction plate. We screened forC. trachomatis and N. gonorrhoeae using the Applied Biosystems™ TaqMan® Assays. The following commercial primers and probes (Ba04646249_S1 and Ba04646252_S1; Thermo Fisher Scientific, Waltham, Massachusetts, United States of America) were used for each organism, respectively. The Ba04646249_S1 targets the translocated actin-recruiting phosphoprotein gene of C. trachomatis, and Ba04646252_S1 targets the hypothetical protein gene of N. gonorrhoeae. Each PCR reaction was performed in a final volume of 20 μl comprising 1 μl FAM-labeled probe/primer mix, 5 μl Fast Start 4x probe master mix (Thermo Fisher, Part No. 4444434), 2 μl template DNA, and 11 μl nuclease-free water. Nontemplate and positive controls (TaqMan™ Vaginal Microbiota Extraction Control; cat no. A32039) were also included. Amplification was performed at 95°C for 30 seconds followed by 45 cycles comprising of denaturation at 95°C for 3 seconds and annealing at 60°C for 30 seconds. Detection of amplified fluorescent products was carried out at the end of the annealing phase. The raw fluorescent data that included the CT mean values were automatically generated by the Quant Studio 5 Real-time PCR system software.


### 2.5. Data Analyses

The statistical data analysis was conducted in the R Statistical computing software of the R Core Team, 2020, version 3.6.3. The descriptive statistics of numerical measurements were summarized as the minimum, maximum, quartiles, interquartile range, means, standard deviation, and the coefficient of variation. On the other hand, the categorical variables were described as counts and percentage frequencies. Depending on the distribution of the numerical variables between two independent groups, mean or median differences were assessed using eithert-test or Wilcoxon test, respectively. To determine the association between categorical variables, a chi-square test was used, and when the distribution of the cross tabulations contained an expected value of less than five, a Fisher’s exact test was applied. Binary logistic regression was used to determine the factors associated with infection and presented as odds ratios. All the inferential statistical analysis tests were conducted at 5% levels of significance.


## 2.1. Ethical Statement

Ethics approval for this study (BREC/00001382/2020) was obtained from the Biomedical Research Ethics Committee (BREC), University of KZN.


## 2.2. Study Population

This was a cross-sectional study among pregnant women, attending the antenatal clinic (ANC) at the King Edward VIII Hospital in Durban, South Africa. At the clinic, women were educated on the consequences of STIs during pregnancy and provided with information on risk reduction for STIs. The clinic attends to 80 to 100 women on a daily basis, and the recruitment for this study took place between October 2020 and April 2021. Women were enrolled in this study if they were HIV infected, 18 years and older, willing to provide written informed consent, willing to provide vaginal swab samples, and willing to provide sociodemographic, behavioral, and clinical data. Patients were explained the process of self-sample collection. Each enrolled women provided self-collected vaginal swabs (dry swabs) for detection of the vaginal infections. The consenting women had also completed a questionnaire on sociodemographic, behavioral, and clinical factors.


## 2.3. Laboratory Procedures

### 2.3.1. Sample Processing

After collection, the dry swabs were placed in 2 ml of phosphate buffered saline (PBS). The solution was vortexed to dislodge the cells from the swabs, and the swab was discarded. The remaining suspension was centrifuged at 14,000 rpm for 10 mins, and the supernatant was discarded. Recovered pellets were then subjected to further molecular analysis.


### 2.3.2. DNA Extraction

DNA extraction was performed on the vaginal fluid pellets using the PureLink Microbiome Kit (Thermo Fisher Scientific, United States), according to the manufacturer’s instructions. Briefly, 2 ml of the vaginal fluid samples was centrifuged for 30 minutes at14000×g. The supernatant was discarded, and 800 μl of S1 lysis buffer was added to the pellet and pipetted up and down to mix the sample. The sample was then transferred to the bead tube, and 100 μl of S2 lysis enhancer was added to the bead tube, capped, and vortexed briefly. This was incubated at 95°C for 10 minutes, followed by vortexing at a maximum speed for 7 minutes and further centrifuged at 14000×g for 1 minute. Thereafter, 500 μl of the supernatant was transferred to a clean microcentrifuge tube, avoiding the bead pellet and any cell debris. To bind DNA to the column, 900 μl of binding buffer was added and vortexed briefly. Following this, 700 μl of the sample mixture was loaded onto a spin column-tube and centrifuged at 14000×g for 1 minute. The flow through was discarded, and the spin column was centrifuged at 14000×g for 30 seconds. The spin column was placed in a clean tube; 50 μl of S6 elution buffer was added, and the tube was incubated at room temperature for 1 minute. After 1 minute, the spin column was centrifuged at 14000×g for 1 minute, and the column was discarded, and the purified DNA was stored at -20°C. The concentration of extracted DNA was determined using the NanoDrop spectrophotometer (Thermo Fisher Scientific, United States). DNA samples were stored at –20°C until further molecular analysis. The molecular assays were conducted at the School of Clinical Medicine’s Research Laboratory at the University of KZN.


## 2.3.1. Sample Processing

After collection, the dry swabs were placed in 2 ml of phosphate buffered saline (PBS). The solution was vortexed to dislodge the cells from the swabs, and the swab was discarded. The remaining suspension was centrifuged at 14,000 rpm for 10 mins, and the supernatant was discarded. Recovered pellets were then subjected to further molecular analysis.


## 2.3.2. DNA Extraction

DNA extraction was performed on the vaginal fluid pellets using the PureLink Microbiome Kit (Thermo Fisher Scientific, United States), according to the manufacturer’s instructions. Briefly, 2 ml of the vaginal fluid samples was centrifuged for 30 minutes at14000×g. The supernatant was discarded, and 800 μl of S1 lysis buffer was added to the pellet and pipetted up and down to mix the sample. The sample was then transferred to the bead tube, and 100 μl of S2 lysis enhancer was added to the bead tube, capped, and vortexed briefly. This was incubated at 95°C for 10 minutes, followed by vortexing at a maximum speed for 7 minutes and further centrifuged at 14000×g for 1 minute. Thereafter, 500 μl of the supernatant was transferred to a clean microcentrifuge tube, avoiding the bead pellet and any cell debris. To bind DNA to the column, 900 μl of binding buffer was added and vortexed briefly. Following this, 700 μl of the sample mixture was loaded onto a spin column-tube and centrifuged at 14000×g for 1 minute. The flow through was discarded, and the spin column was centrifuged at 14000×g for 30 seconds. The spin column was placed in a clean tube; 50 μl of S6 elution buffer was added, and the tube was incubated at room temperature for 1 minute. After 1 minute, the spin column was centrifuged at 14000×g for 1 minute, and the column was discarded, and the purified DNA was stored at -20°C. The concentration of extracted DNA was determined using the NanoDrop spectrophotometer (Thermo Fisher Scientific, United States). DNA samples were stored at –20°C until further molecular analysis. The molecular assays were conducted at the School of Clinical Medicine’s Research Laboratory at the University of KZN.


## 2.4. Detection of STI Pathogens

PCR amplification was performed on the Quant Studio 5 real-time PCR detection system (Thermo Fisher Scientific, Waltham, Massachusetts, United States of America), in a 96-well microtiter reaction plate. We screened forC. trachomatis and N. gonorrhoeae using the Applied Biosystems™ TaqMan® Assays. The following commercial primers and probes (Ba04646249_S1 and Ba04646252_S1; Thermo Fisher Scientific, Waltham, Massachusetts, United States of America) were used for each organism, respectively. The Ba04646249_S1 targets the translocated actin-recruiting phosphoprotein gene of C. trachomatis, and Ba04646252_S1 targets the hypothetical protein gene of N. gonorrhoeae. Each PCR reaction was performed in a final volume of 20 μl comprising 1 μl FAM-labeled probe/primer mix, 5 μl Fast Start 4x probe master mix (Thermo Fisher, Part No. 4444434), 2 μl template DNA, and 11 μl nuclease-free water. Nontemplate and positive controls (TaqMan™ Vaginal Microbiota Extraction Control; cat no. A32039) were also included. Amplification was performed at 95°C for 30 seconds followed by 45 cycles comprising of denaturation at 95°C for 3 seconds and annealing at 60°C for 30 seconds. Detection of amplified fluorescent products was carried out at the end of the annealing phase. The raw fluorescent data that included the CT mean values were automatically generated by the Quant Studio 5 Real-time PCR system software.


## 2.5. Data Analyses

The statistical data analysis was conducted in the R Statistical computing software of the R Core Team, 2020, version 3.6.3. The descriptive statistics of numerical measurements were summarized as the minimum, maximum, quartiles, interquartile range, means, standard deviation, and the coefficient of variation. On the other hand, the categorical variables were described as counts and percentage frequencies. Depending on the distribution of the numerical variables between two independent groups, mean or median differences were assessed using eithert-test or Wilcoxon test, respectively. To determine the association between categorical variables, a chi-square test was used, and when the distribution of the cross tabulations contained an expected value of less than five, a Fisher’s exact test was applied. Binary logistic regression was used to determine the factors associated with infection and presented as odds ratios. All the inferential statistical analysis tests were conducted at 5% levels of significance.


## 3. Results

### 3.1. Prevalence Estimates and Actual Risk versus Perceived Risk

Of the total 385 HIV-infected women who were enrolled in this study, the prevalence of the individual STIs was as follows:C. trachomatis (47/385, 12.2%) and N. gonorrhoeae (16/385, 4.1%) (Tables 1 and 2). The Ct values of the samples are shown in Supplementary Table S1. According to the Ct values, using a cut-off value of 25 for distinguishing low and high positives (<25 high positive, >25 low positive), 43 samples were low positive,s and four samples were high positives were C. trachomatis, and 16 samples were low positives, and none of the samples were high positives were N. gonorrhoeae.Table 1
Characteristics of the study population based onC. trachomatis status.
C. trachomatisNegative (N=338)Positive (N=47)p valueOverall (N=385)Age<0.001Mean±SD (CV%)30.8±6.50 (21.1)26.7±6.27 (23.5)30.3±6.60 (21.8)Median (Q1-Q3)31.0 (26.0-37.0)26.0 (21.5-32.0)30.0 (25.0-36.0)Min-max18.0-44.018.0-39.018.0-44.0Educational level0.090Primary school and below8 (2.4%)1 (2.1%)9 (2.3%)High school255 (75.4%)42 (89.4%)297 (77.1%)College, university75 (22.2%)4 (8.5%)79 (20.5%)Employed0.089No249 (73.7%)40 (85.1%)289 (75.1%)Yes89 (26.3%)7 (14.9%)96 (24.9%)Married0.020No290 (85.8%)46 (97.9%)336 (87.3%)Yes48 (14.2%)1 (2.1%)49 (12.7%)Has a regular sex partner0.180No18 (5.3%)5 (10.6%)23 (6.0%)Yes320 (94.7%)42 (89.4%)362 (94.0%)Partner’s HIV status0.174Negative127 (37.6%)21 (44.7%)148 (38.4%)Positive162 (47.9%)16 (34.0%)178 (46.2%)Do not know49 (14.5%)10 (21.3%)59 (15.3%)Cohabiting with sex partner0.066No196 (58.3%)34 (72.3%)230 (60.1%)Yes140 (41.7%)13 (27.7%)153 (39.9%)Age of 1st sex0.009< 15 yrs7 (2.1%)5 (10.6%)12 (3.1%)15-20 yrs238 (70.4%)36 (76.6%)274 (71.2%)21-25 yrs86 (25.4%)6 (12.8%)92 (23.9%)> 25 yrs7 (2.1%)0 (0.0%)7 (1.8%)Lifetime number of sex partners0.683196 (28.4%)11 (23.4%)107 (27.8%)2-4165 (48.8%)26 (55.3%)191 (49.6%)> 477 (22.8%)10 (21.3%)87 (22.6%)Partner has other partners0.565Do not know159 (47.0%)26 (55.3%)185 (48.1%)No96 (28.4%)11 (23.4%)107 (27.8%)Yes83 (24.6%)10 (21.3%)93 (24.2%)Condom used during last sex0.464No219 (64.8%)33 (70.2%)252 (65.5%)Yes119 (35.2%)14 (29.8%)133 (34.5%)Partner is circumcised0.041No115 (34.0%)9 (19.1%)124 (32.2%)Yes223 (66.0%)38 (80.9%)261 (67.8%)Trimester of pregnancy0.5111st24 (7.1%)5 (10.9%)29 (7.5%)2nd110 (32.5%)12 (26.1%)122 (31.8%)3rd204 (60.4%)29 (63.0%)233 (60.7%)Previously treatment for STIs0.026No218 (64.5%)38 (80.9%)256 (66.5%)Yes120 (35.5%)9 (19.1%)129 (33.5%)Engages in intravaginal practices1.000No317 (93.8%)45 (95.7%)362 (94.0%)Yes21 (6.2%)2 (4.3%)23 (6.0%)Perceived risk of getting STIs0.274No136 (40.2%)15 (31.9%)151 (39.2%)Yes202 (59.8%)32 (68.1%)234 (60.8%)Partner STI symptoms0.933No275 (81.4%)38 (80.9%)313 (81.3%)Yes63 (18.6%)9 (19.1%)72 (18.7%)Current symptoms of STI0.754No215 (63.6%)31 (66.0%)246 (63.9%)Yes123 (34.0%)16 (34.0%)139 (36.1%)N. gonorrhoeae status0.001Negative329 (97.3%)40 (85.1%)369 (95.8%)Positive9 (2.7%)7 (14.9%)16 (4.2%)Table 2
Characteristics of the study population based onN. gonorrhoeae status.
N. gonorrhoeaeNegative (N=369)Positive (N=16)p valueOverall (N=385)Age0.004Mean±SD (CV%)30.5±6.60 (21.6)25.8±4.80 (18.6)30.3±6.60 (21.8)Median(Q1-Q3)30.0 (25.0-36.0)24.5 (21.8-29.3)30.0 (25.0-36.0)Min-max18.0-44.019.0-34.018.0-44.0Educational level0.687Primary school and below9 (2.4%)0 (0.0%)9 (2.3%)High school283 (76.7%)14 (87.5%)297 (77.1%)College, university77 (20.9%)2 (12.5%)79 (20.5%)Employed1.000No277 (75.1%)12 (75.0%)289 (75.1%)Yes92 (24.9%)4 (25.0%)96 (24.9%)Married1.000No322 (87.3%)14 (87.5%)336 (87.3%)Yes47 (12.7%)2 (12.5%)49 (12.7%)Has a regular sex partner0.612No23 (6.2%)0 (0.0%)23 (6.0%)Yes346 (93.8%)16 (100.0%)362 (94.0%)Partner’s HIV status0.006Negative144 (39.0%)4 (25.0%)148 (38.4%)Positive173 (46.9%)5 (31.3%)178 (46.2%)Do not know52 (14.1%)7 (43.8%)59 (15.3%)Cohabiting with sex partner0.212No218 (59.4%)12 (75.0%)230 (60.1%)Yes149 (40.6%)4 (25.0%)153 (39.9%)Age of 1st sex0.185< 15 yrs11 (3.0%)1 (6.2%)12 (3.1%)15-20 yrs262 (71.0%)12 (75.0%)274 (71.2%)21-25 yrs90 (24.4%)2 (12.5%)92 (23.9%)> 25 yrs6 (1.6%)1 (6.2%)7 (1.8%)Lifetime number of sex partners0.7941104 (28.2%)3 (18.8%)107 (27.8%)2-4182 (49.3%)9 (56.3%)191 (49.6%)> 483 (22.5%)4 (25.0%)87 (22.6%)Partner has other partners0.026Do not know178 (48.2%)7 (43.8%)185 (48.1%)No106 (28.7%)1 (6.2%)107 (27.8%)Yes85 (23.0%)8 (50.0%)93 (24.2%)Condom used during last sex0.175No239 (64.8%)13 (81.3%)252 (65.5%)Yes130 (35.2%)3 (18.8%)133 (34.5%)Partner circumcised0.239No121 (32.8%)3 (18.8%)124 (32.2%)Yes248 (67.2%)13 (81.3%)261 (67.8%)Trimester pregnancy0.2161st26 (7.1%)3 (18.8%)29 (7.5%)2nd118 (32.1%)4 (25.0%)122 (31.8%)3rd224 (60.9%)9 (56.3%)233 (60.7%)Previously treatment for STIs0.845No245 (66.4%)11 (68.8%)256 (66.5%)Yes124 (33.6%)5 (31.3%)129 (33.5%)Engages in intravaginal practices0.246No348 (94.3%)14 (87.5%)362 (94.0%)Yes21 (5.7%)2 (12.5%)23 (6.0%)Partner has STI symptoms0.325No298 (80.8%)15 (93.8%)313 (81.3%)Yes71 (19.2%)1 (6.2%)72 (18.7%)Current symptoms of STI0.680No235 (63.7%)11 (68.8%)246 (63.9%)Yes134 (36.3%)5 (31.3%)139 (36.1%)C. trachomatis status0.001Negative329 (89.2%)9 (56.3%)338 (87.8%)Positive40 (10.8%)7 (43.8%)47 (12.2%)Perceived risk of getting STIs0.505No146 (39.6%)5 (31.3%)151 (39.2%)Yes223 (60.4%)11 (68.8%)234 (60.8%)For the women who tested negative forC. trachomatis, 31.9% reported that they were not at risk for contracting an STI. The majority of women (68.1%) who perceived themselves for being at risk for infection tested positive. However, there was no significant association between risk perception and infection status for C. trachomatis (p=0.274; Table 1).ForN. gonorrhoeae, a similar trend was observed; a larger percentage of the women (68.8%) who perceived themselves at being at risk for contracting the STI tested positive. Despite the high percentage of women being at actual risk, there was no significance (p=0.505) between actual versus perceived risk for this pathogen (Table 2).


### 3.2. Characteristics of the Study Women according toC. trachomatis Status

There was a significant difference (p<0.001) in age across the women who tested C. trachomatis negative and positive. The women who tested positive were younger (median age: 26.0; interquartile range: 21.5-32.0) when compared to the women who tested negative (median age: 31.0; interquartile range: 26.0-37.0). Factors significantly associated with C. trachomatis status included marital status, age of first sex, partner being circumcised, previous treatment for STIs, and N. gonorrhoeae status. A higher proportion of unmarried women (97.9%) tested positive for C. trachomatis when compared to 85.8% who tested negative (p=0.020). A higher proportion of women who had experienced first sex younger than 15 years of age tested C. trachomatis positive (10.6%) when compared to 2.1% who tested negative for infection (p=0.009). Having a circumcised partner does not protect against infection. For the women who reported having a circumcised partner, a lower proportion tested negative for infection (66.0%) when compared to 80.9% who tested C. trachomatis positive (p=0.041). Having a history of STI treatment protected against infection showing that 35.5% tested negative for infection when compared to 19.1% who tested positive (p=0.026). A higher proportion (14.9%) of women who tested positive for N. gonorrhoeae also tested positive for C. trachomatis when compared to 2.7% who tested negative (p=0.001; Table 1).


### 3.3. Characteristics of the Study Women Who TestedN. gonorrhoeae Positive

There was a significant difference (p=0.004) in age across the women who tested N. gonorrhoeae negative and positive. The women who tested positive were younger (median age: 24.5; interquartile range: 21.8-29.3) when compared to the women who tested negative (median age: 30.0; interquartile range: 25.0-36.0). Other factors significantly associated with N. gonorrhoeae status included partner’s HIV status, partner having other partners, and C. trachomatis status. A higher proportion of women who did not know their partner’s HIV status tested positive for N. gonorrhoeae (43.8%) when compared to 14.1% who tested negative for infection (p=0.006). A higher proportion of women who reported that their partner had other partners tested positive for N. gonorrhoeae (50.0%) when compared to 23.0% who tested negative (p=0.026). Of the women who tested C. trachomatis positive, a higher proportion (43.8%) tested positive for N. gonorrhoeae when compared to 10.8% who tested negative (p=0.001; Table 2).


### 3.4. Risk Factors forC. trachomatis Infection

The following factors were associated with the increased risk of acquiringC. trachomatis infection: partner being circumcised, perceiving one’s self at being at risk for infection, and N. gonorrhoeae infection status (Table 3).Table 3
Risk factors forC. trachomatis infection.
FactorUnadjusted analysisOdds ratio with 95% confidence intervalsFull adjusted analysisOdds ratio with 95% confidence intervalsBackstep analysisOdds ratio with 95% confidence intervalsAge0.86 (0.80-0.91,p<0.001)0.91 (0.84-0.99,p=0.041)0.91 (0.84-0.98,p=0.020)Being employed0.29 (0.07-0.83,p=0.044)0.19 (0.03-0.79,p=0.040)0.30 (0.06-1.04,p=0.085)Having a regular sex partner0.52 (0.16-2.30,p=0.312)0.91 (0.19-5.61,p=0.909)—Having an HIV-positive partner0.71 (0.31-1.62,p=0.417)1.21 (0.42-3.47,p=0.722)—Not knowing partner’s HIV status1.37 (0.49-3.56,p=0.524)1.05 (0.26-3.83,p=0.946)—Cohabiting with partner0.32 (0.12-0.76,p=0.015)0.90 (0.25-2.99,p=0.865)—Age of 1st sex, 15-20 yrs0.16 (0.04-0.68,p=0.008)0.26 (0.05-1.44,p=0.112)0.23 (0.05-1.24,p=0.072)Age of 1st sex, 21+ yrs0.03 (0.00-0.20,p<0.001)0.09 (0.01-0.78,p=0.035)0.08 (0.01-0.63,p=0.020)Having 2-4 lifetime number of sex partners1.67 (0.71-4.39,p=0.261)2.69 (0.88-9.37,p=0.098)—Having >4 lifetime sex partners0.90 (0.26-2.94,p=0.865)1.25 (0.24-6.09,p=0.787)—Partner does not have other partners0.42 (0.13-1.07,p=0.089)0.40 (0.10-1.34,p=0.155)—Partner has other partners0.67 (0.25-1.57,p=0.377)0.32 (0.08-1.04,p=0.073)—Used a condom during last0.62 (0.25-1.36,p=0.253)0.50 (0.16-1.44,p=0.219)—Having a partner who is circumcised5.03 (1.74-21.32,p=0.009)4.28 (1.27-20.05,p=0.033)3.86 (1.21-17.27,p=0.039)Trimester pregnancy 2nd0.65 (0.18-3.11,p=0.547)1.31 (0.24-9.36,p=0.769)—Trimester pregnancy 3rd0.79 (0.25-3.53,p=0.722)1.32 (0.25-9.26,p=0.758)—Having been previously treated for STIs0.19 (0.04-0.54,p=0.006)0.12 (0.02-0.44,p=0.004)0.16 (0.03-0.51,p=0.006)Engages in intravaginal practices0.48 (0.03-2.44,p=0.485)0.23 (0.01-2.30,p=0.298)—Perceived one’s self at risk for STIs2.01 (0.91-4.91,p=0.098)2.41 (0.89-7.14,p=0.094)2.85 (1.16-7.68,p=0.028)BeingN. gonorrhoeae positive10.17 (3.39-29.66,p<0.001)11.93 (2.60-60.62,p=0.002)9.16 (2.19-40.18,p=0.003)Having a circumcised partner, testing positive forN. gonorrhoeae, and perceiving themselves of being at risk for infection were shown to increase the risk for C. trachomatis infection. In the unadjusted analysis, having a circumcised partner increased the risk for infection by 5-fold (odds ratio (OR): 5.03, 95% confidence interval (CI): 1.74-21.32, p=0.009). After controlling for confounders, having a circumcised partner increased the risk for infection by close to 4-fold (OR: 3.86, 95% CI: 1.21-17.27, p=0.039). Perceiving one’s self to be at risk for infection was shown to increase the risk for infection by greater than 2.5-fold in the adjusted analysis only (OR: 2.85, 95% CI: 1.16-7.68, p=0.028). Testing positive for N. gonorrhoeae increased the risk for C. trachomatis infection by 10-fold in the unadjusted analysis (OR: 10.17, 95% CI: 3.39-29.66, p<0.001). Similarly, after controlling for confounders, the risk for C. trachomatis infection in women who tested positive for N. gonorrhoeae was 9-fold (OR: 9.16, 95% CI: 2.19-40.18, p=0.003).However, in the unadjusted analysis, having sex at an older age, i.e., older than 21 years of age, reduced the risk of getting infected withC. trachomatis (OR: 0.03, 95% CI: 0.00-0.20, p<0.001). This association was also shown to be significant in the adjusted analysis (OR: 0.08, 95% CI: 0.01-0.63, p=0.020). Having been previously treated for STIs also reduced the risk for C. trachomatis infection, both in the unadjusted and adjusted analysis (OR: 0.19, 95% CI: 0.04-0.54, p=0.006, and OR: 0.16, 95% CI: 0.03-0.51, p=0.006, respectively). In the unadjusted analysis, cohabiting with a partner also reduced the risk of getting infected with C. trachomatis (OR: 0.32, 95% CI: 0.12-0.76, p=0.015) (Table 3).


### 3.5. Risk Factors forN. gonorrhoeae Infection

The following factors were associated with the increased risk of acquiringN. gonorrhoeae infection: not knowing their partner’s HIV status, partner having other partners, engaging in intravaginal practices, and being C. trachomatis positive (Table 4).Table 4
Risk factors forN. gonorrhoeae infection.
FactorUnadjusted analysisOdds ratio with 95% confidence intervalsFull adjusted analysisOdds ratio with 95% confidence intervalsBackstep analysisOdds ratio with 95% confidence intervalsAge0.89 (0.81-0.96,p=0.007)0.84 (0.72-0.95,p=0.011)0.89 (0.80-0.98,p=0.023)Being employed0.99 (0.27-2.93,p=0.990)1.58 (0.30-7.22,p=0.566)—Married yes0.97 (0.15-3.62,p=990)2.09 (0.16-21.64,p=0.544)—Having an HIV-positive partner1.02 (0.26-4.18,p=0.978)1.80 (0.38-9.51,p=0.463)1.79 (0.41-8.78,p=0.445)Not knowing partner’s HIV status4.75 (1.38-18.74,p=0.016)6.72 (1.44-37.95,p=0.019)5.73(1.35-28.71,p=0.022)Cohabiting with partner0.49 (0.13-1.42,p=0.218)1.33 (0.23-6.68,p=0.734)—Age of 1st sex, 15-20 yrs0.46 (0.08-8.81,p=0.478)1.05 (0.11-28.79,p=0.971)—Age of 1st sex, 21+ yrs0.31 (0.04-6.64,p=0.333)1.80 (0.09-70.09,p=0.715)—Having 2-4 lifetime number of sex partners1.73 (0.50-7.94,p=0.417)1.65 (0.37-9.34,p=0.531)—Having >4 lifetime sex partners1.69 (0.36-8.78,p=0.499)1.65 (0.23-12.77,p=0.616)—Partner does not have other partners0.24 (0.01-1.37,p=0.184)0.11 (0.00-1.13,p=0.114)0.14 (0.01-1.07,p=0.106)Partner has other partners2.37 (0.82-6.96,p=0.107)3.67 (0.95-15.58,p=0.064)3.91 (1.13-14.65,p=0.034)Used a condom during last0.43 (0.10-1.36,p=0.193)0.47 (0.08-1.97,p=0.338)—Having a partner who is circumcised2.14 (0.67-9.46,p=0.242)1.29 (0.28-7.77,p=0.762)—Trimester pregnancy 2nd0.29 (0.06-1.56,p=0.123)0.15 (0.02-1.12,p=0.059)0.16 (0.03-1.03,p=0.045)Trimester pregnancy 3rd0.35 (0.10-1.66,p=0.134)0.14 (0.02-0.90,p=0.030)0.13 (0.02-0.76,p=0.016)Having been previously treated for STIs0.89 (0.27-2.50,p=0.828)2.33 (0.55-9.84,p=0.239)—Engages in intravaginal practices2.35 (0.35-9.16,p=0.279)5.10 (0.61-32.40,p=0.093)5.83 (0.76-31.51,p=0.052)Perceived one’s self at risk for STIs1.44 (0.51-4.66,p=0.504)1.29 (0.33-5.74,p=0.726)—Being C. trachomatis positive6.52 (2.22-18.49,p<0.001)7.95 (1.90-36.62,p=0.005)6.09 (1.73-22.03,p=0.005)In the unadjusted analysis, not knowing their partner’s HIV status increased the risk for infection by 4-fold (OR: 4.75, 95% CI: 1.38-28.71,p=0.016). Similarly, in the adjusted analysis, not knowing their partner’s HIV status increased the risk for infection by 5-fold (OR: 5.73, 95% CI: 1.35-28.71, p=0.022), and this was significant. In the adjusted analysis, women who reported that their partner had other partners had a close to 4-fold increased risk of getting infected, and this was significant (OR: 3.91, 95% CI: 1.13-14.65, p=0.034). Engaging in intravaginal practices increased the risk of infection by 5-fold (OR: 5.83, 95% CI: 0.76-31.51, p=0.052) in the adjusted analysis. Testing positive for C. trachomatis increased the risk for N. gonorrhoeae infection by 6-fold in the unadjusted analysis (OR: 6.52, 95% CI: 2.22-18.49, p<0.001). Similarly, in the adjusted analysis, the risk for N. gonorrhoeae infection in women who tested positive C. trachomatis increased by 6-fold (OR: 6.09, 95% CI: 1.73-22.03, p=0.005), and this association was significant. However, in the adjusted analysis, being in the second and third trimesters of pregnancy reduced the risk of getting infected with N. gonorrhoeae (odds ratio (OR): 0.16, 95% confidence interval (95% CI): 0.03-1.03, p=0.045, and OR: 0.13, 95% CI: 0.02-0.76, p=0.016, respectively) Table 4).


## 3.1. Prevalence Estimates and Actual Risk versus Perceived Risk

Of the total 385 HIV-infected women who were enrolled in this study, the prevalence of the individual STIs was as follows:C. trachomatis (47/385, 12.2%) and N. gonorrhoeae (16/385, 4.1%) (Tables 1 and 2). The Ct values of the samples are shown in Supplementary Table S1. According to the Ct values, using a cut-off value of 25 for distinguishing low and high positives (<25 high positive, >25 low positive), 43 samples were low positive,s and four samples were high positives were C. trachomatis, and 16 samples were low positives, and none of the samples were high positives were N. gonorrhoeae.Table 1
Characteristics of the study population based onC. trachomatis status.
C. trachomatisNegative (N=338)Positive (N=47)p valueOverall (N=385)Age<0.001Mean±SD (CV%)30.8±6.50 (21.1)26.7±6.27 (23.5)30.3±6.60 (21.8)Median (Q1-Q3)31.0 (26.0-37.0)26.0 (21.5-32.0)30.0 (25.0-36.0)Min-max18.0-44.018.0-39.018.0-44.0Educational level0.090Primary school and below8 (2.4%)1 (2.1%)9 (2.3%)High school255 (75.4%)42 (89.4%)297 (77.1%)College, university75 (22.2%)4 (8.5%)79 (20.5%)Employed0.089No249 (73.7%)40 (85.1%)289 (75.1%)Yes89 (26.3%)7 (14.9%)96 (24.9%)Married0.020No290 (85.8%)46 (97.9%)336 (87.3%)Yes48 (14.2%)1 (2.1%)49 (12.7%)Has a regular sex partner0.180No18 (5.3%)5 (10.6%)23 (6.0%)Yes320 (94.7%)42 (89.4%)362 (94.0%)Partner’s HIV status0.174Negative127 (37.6%)21 (44.7%)148 (38.4%)Positive162 (47.9%)16 (34.0%)178 (46.2%)Do not know49 (14.5%)10 (21.3%)59 (15.3%)Cohabiting with sex partner0.066No196 (58.3%)34 (72.3%)230 (60.1%)Yes140 (41.7%)13 (27.7%)153 (39.9%)Age of 1st sex0.009< 15 yrs7 (2.1%)5 (10.6%)12 (3.1%)15-20 yrs238 (70.4%)36 (76.6%)274 (71.2%)21-25 yrs86 (25.4%)6 (12.8%)92 (23.9%)> 25 yrs7 (2.1%)0 (0.0%)7 (1.8%)Lifetime number of sex partners0.683196 (28.4%)11 (23.4%)107 (27.8%)2-4165 (48.8%)26 (55.3%)191 (49.6%)> 477 (22.8%)10 (21.3%)87 (22.6%)Partner has other partners0.565Do not know159 (47.0%)26 (55.3%)185 (48.1%)No96 (28.4%)11 (23.4%)107 (27.8%)Yes83 (24.6%)10 (21.3%)93 (24.2%)Condom used during last sex0.464No219 (64.8%)33 (70.2%)252 (65.5%)Yes119 (35.2%)14 (29.8%)133 (34.5%)Partner is circumcised0.041No115 (34.0%)9 (19.1%)124 (32.2%)Yes223 (66.0%)38 (80.9%)261 (67.8%)Trimester of pregnancy0.5111st24 (7.1%)5 (10.9%)29 (7.5%)2nd110 (32.5%)12 (26.1%)122 (31.8%)3rd204 (60.4%)29 (63.0%)233 (60.7%)Previously treatment for STIs0.026No218 (64.5%)38 (80.9%)256 (66.5%)Yes120 (35.5%)9 (19.1%)129 (33.5%)Engages in intravaginal practices1.000No317 (93.8%)45 (95.7%)362 (94.0%)Yes21 (6.2%)2 (4.3%)23 (6.0%)Perceived risk of getting STIs0.274No136 (40.2%)15 (31.9%)151 (39.2%)Yes202 (59.8%)32 (68.1%)234 (60.8%)Partner STI symptoms0.933No275 (81.4%)38 (80.9%)313 (81.3%)Yes63 (18.6%)9 (19.1%)72 (18.7%)Current symptoms of STI0.754No215 (63.6%)31 (66.0%)246 (63.9%)Yes123 (34.0%)16 (34.0%)139 (36.1%)N. gonorrhoeae status0.001Negative329 (97.3%)40 (85.1%)369 (95.8%)Positive9 (2.7%)7 (14.9%)16 (4.2%)Table 2
Characteristics of the study population based onN. gonorrhoeae status.
N. gonorrhoeaeNegative (N=369)Positive (N=16)p valueOverall (N=385)Age0.004Mean±SD (CV%)30.5±6.60 (21.6)25.8±4.80 (18.6)30.3±6.60 (21.8)Median(Q1-Q3)30.0 (25.0-36.0)24.5 (21.8-29.3)30.0 (25.0-36.0)Min-max18.0-44.019.0-34.018.0-44.0Educational level0.687Primary school and below9 (2.4%)0 (0.0%)9 (2.3%)High school283 (76.7%)14 (87.5%)297 (77.1%)College, university77 (20.9%)2 (12.5%)79 (20.5%)Employed1.000No277 (75.1%)12 (75.0%)289 (75.1%)Yes92 (24.9%)4 (25.0%)96 (24.9%)Married1.000No322 (87.3%)14 (87.5%)336 (87.3%)Yes47 (12.7%)2 (12.5%)49 (12.7%)Has a regular sex partner0.612No23 (6.2%)0 (0.0%)23 (6.0%)Yes346 (93.8%)16 (100.0%)362 (94.0%)Partner’s HIV status0.006Negative144 (39.0%)4 (25.0%)148 (38.4%)Positive173 (46.9%)5 (31.3%)178 (46.2%)Do not know52 (14.1%)7 (43.8%)59 (15.3%)Cohabiting with sex partner0.212No218 (59.4%)12 (75.0%)230 (60.1%)Yes149 (40.6%)4 (25.0%)153 (39.9%)Age of 1st sex0.185< 15 yrs11 (3.0%)1 (6.2%)12 (3.1%)15-20 yrs262 (71.0%)12 (75.0%)274 (71.2%)21-25 yrs90 (24.4%)2 (12.5%)92 (23.9%)> 25 yrs6 (1.6%)1 (6.2%)7 (1.8%)Lifetime number of sex partners0.7941104 (28.2%)3 (18.8%)107 (27.8%)2-4182 (49.3%)9 (56.3%)191 (49.6%)> 483 (22.5%)4 (25.0%)87 (22.6%)Partner has other partners0.026Do not know178 (48.2%)7 (43.8%)185 (48.1%)No106 (28.7%)1 (6.2%)107 (27.8%)Yes85 (23.0%)8 (50.0%)93 (24.2%)Condom used during last sex0.175No239 (64.8%)13 (81.3%)252 (65.5%)Yes130 (35.2%)3 (18.8%)133 (34.5%)Partner circumcised0.239No121 (32.8%)3 (18.8%)124 (32.2%)Yes248 (67.2%)13 (81.3%)261 (67.8%)Trimester pregnancy0.2161st26 (7.1%)3 (18.8%)29 (7.5%)2nd118 (32.1%)4 (25.0%)122 (31.8%)3rd224 (60.9%)9 (56.3%)233 (60.7%)Previously treatment for STIs0.845No245 (66.4%)11 (68.8%)256 (66.5%)Yes124 (33.6%)5 (31.3%)129 (33.5%)Engages in intravaginal practices0.246No348 (94.3%)14 (87.5%)362 (94.0%)Yes21 (5.7%)2 (12.5%)23 (6.0%)Partner has STI symptoms0.325No298 (80.8%)15 (93.8%)313 (81.3%)Yes71 (19.2%)1 (6.2%)72 (18.7%)Current symptoms of STI0.680No235 (63.7%)11 (68.8%)246 (63.9%)Yes134 (36.3%)5 (31.3%)139 (36.1%)C. trachomatis status0.001Negative329 (89.2%)9 (56.3%)338 (87.8%)Positive40 (10.8%)7 (43.8%)47 (12.2%)Perceived risk of getting STIs0.505No146 (39.6%)5 (31.3%)151 (39.2%)Yes223 (60.4%)11 (68.8%)234 (60.8%)For the women who tested negative forC. trachomatis, 31.9% reported that they were not at risk for contracting an STI. The majority of women (68.1%) who perceived themselves for being at risk for infection tested positive. However, there was no significant association between risk perception and infection status for C. trachomatis (p=0.274; Table 1).ForN. gonorrhoeae, a similar trend was observed; a larger percentage of the women (68.8%) who perceived themselves at being at risk for contracting the STI tested positive. Despite the high percentage of women being at actual risk, there was no significance (p=0.505) between actual versus perceived risk for this pathogen (Table 2).


## 3.2. Characteristics of the Study Women according toC. trachomatis Status

There was a significant difference (p<0.001) in age across the women who tested C. trachomatis negative and positive. The women who tested positive were younger (median age: 26.0; interquartile range: 21.5-32.0) when compared to the women who tested negative (median age: 31.0; interquartile range: 26.0-37.0). Factors significantly associated with C. trachomatis status included marital status, age of first sex, partner being circumcised, previous treatment for STIs, and N. gonorrhoeae status. A higher proportion of unmarried women (97.9%) tested positive for C. trachomatis when compared to 85.8% who tested negative (p=0.020). A higher proportion of women who had experienced first sex younger than 15 years of age tested C. trachomatis positive (10.6%) when compared to 2.1% who tested negative for infection (p=0.009). Having a circumcised partner does not protect against infection. For the women who reported having a circumcised partner, a lower proportion tested negative for infection (66.0%) when compared to 80.9% who tested C. trachomatis positive (p=0.041). Having a history of STI treatment protected against infection showing that 35.5% tested negative for infection when compared to 19.1% who tested positive (p=0.026). A higher proportion (14.9%) of women who tested positive for N. gonorrhoeae also tested positive for C. trachomatis when compared to 2.7% who tested negative (p=0.001; Table 1).


## 3.3. Characteristics of the Study Women Who TestedN. gonorrhoeae Positive

There was a significant difference (p=0.004) in age across the women who tested N. gonorrhoeae negative and positive. The women who tested positive were younger (median age: 24.5; interquartile range: 21.8-29.3) when compared to the women who tested negative (median age: 30.0; interquartile range: 25.0-36.0). Other factors significantly associated with N. gonorrhoeae status included partner’s HIV status, partner having other partners, and C. trachomatis status. A higher proportion of women who did not know their partner’s HIV status tested positive for N. gonorrhoeae (43.8%) when compared to 14.1% who tested negative for infection (p=0.006). A higher proportion of women who reported that their partner had other partners tested positive for N. gonorrhoeae (50.0%) when compared to 23.0% who tested negative (p=0.026). Of the women who tested C. trachomatis positive, a higher proportion (43.8%) tested positive for N. gonorrhoeae when compared to 10.8% who tested negative (p=0.001; Table 2).


## 3.4. Risk Factors forC. trachomatis Infection

The following factors were associated with the increased risk of acquiringC. trachomatis infection: partner being circumcised, perceiving one’s self at being at risk for infection, and N. gonorrhoeae infection status (Table 3).Table 3
Risk factors forC. trachomatis infection.
FactorUnadjusted analysisOdds ratio with 95% confidence intervalsFull adjusted analysisOdds ratio with 95% confidence intervalsBackstep analysisOdds ratio with 95% confidence intervalsAge0.86 (0.80-0.91,p<0.001)0.91 (0.84-0.99,p=0.041)0.91 (0.84-0.98,p=0.020)Being employed0.29 (0.07-0.83,p=0.044)0.19 (0.03-0.79,p=0.040)0.30 (0.06-1.04,p=0.085)Having a regular sex partner0.52 (0.16-2.30,p=0.312)0.91 (0.19-5.61,p=0.909)—Having an HIV-positive partner0.71 (0.31-1.62,p=0.417)1.21 (0.42-3.47,p=0.722)—Not knowing partner’s HIV status1.37 (0.49-3.56,p=0.524)1.05 (0.26-3.83,p=0.946)—Cohabiting with partner0.32 (0.12-0.76,p=0.015)0.90 (0.25-2.99,p=0.865)—Age of 1st sex, 15-20 yrs0.16 (0.04-0.68,p=0.008)0.26 (0.05-1.44,p=0.112)0.23 (0.05-1.24,p=0.072)Age of 1st sex, 21+ yrs0.03 (0.00-0.20,p<0.001)0.09 (0.01-0.78,p=0.035)0.08 (0.01-0.63,p=0.020)Having 2-4 lifetime number of sex partners1.67 (0.71-4.39,p=0.261)2.69 (0.88-9.37,p=0.098)—Having >4 lifetime sex partners0.90 (0.26-2.94,p=0.865)1.25 (0.24-6.09,p=0.787)—Partner does not have other partners0.42 (0.13-1.07,p=0.089)0.40 (0.10-1.34,p=0.155)—Partner has other partners0.67 (0.25-1.57,p=0.377)0.32 (0.08-1.04,p=0.073)—Used a condom during last0.62 (0.25-1.36,p=0.253)0.50 (0.16-1.44,p=0.219)—Having a partner who is circumcised5.03 (1.74-21.32,p=0.009)4.28 (1.27-20.05,p=0.033)3.86 (1.21-17.27,p=0.039)Trimester pregnancy 2nd0.65 (0.18-3.11,p=0.547)1.31 (0.24-9.36,p=0.769)—Trimester pregnancy 3rd0.79 (0.25-3.53,p=0.722)1.32 (0.25-9.26,p=0.758)—Having been previously treated for STIs0.19 (0.04-0.54,p=0.006)0.12 (0.02-0.44,p=0.004)0.16 (0.03-0.51,p=0.006)Engages in intravaginal practices0.48 (0.03-2.44,p=0.485)0.23 (0.01-2.30,p=0.298)—Perceived one’s self at risk for STIs2.01 (0.91-4.91,p=0.098)2.41 (0.89-7.14,p=0.094)2.85 (1.16-7.68,p=0.028)BeingN. gonorrhoeae positive10.17 (3.39-29.66,p<0.001)11.93 (2.60-60.62,p=0.002)9.16 (2.19-40.18,p=0.003)Having a circumcised partner, testing positive forN. gonorrhoeae, and perceiving themselves of being at risk for infection were shown to increase the risk for C. trachomatis infection. In the unadjusted analysis, having a circumcised partner increased the risk for infection by 5-fold (odds ratio (OR): 5.03, 95% confidence interval (CI): 1.74-21.32, p=0.009). After controlling for confounders, having a circumcised partner increased the risk for infection by close to 4-fold (OR: 3.86, 95% CI: 1.21-17.27, p=0.039). Perceiving one’s self to be at risk for infection was shown to increase the risk for infection by greater than 2.5-fold in the adjusted analysis only (OR: 2.85, 95% CI: 1.16-7.68, p=0.028). Testing positive for N. gonorrhoeae increased the risk for C. trachomatis infection by 10-fold in the unadjusted analysis (OR: 10.17, 95% CI: 3.39-29.66, p<0.001). Similarly, after controlling for confounders, the risk for C. trachomatis infection in women who tested positive for N. gonorrhoeae was 9-fold (OR: 9.16, 95% CI: 2.19-40.18, p=0.003).However, in the unadjusted analysis, having sex at an older age, i.e., older than 21 years of age, reduced the risk of getting infected withC. trachomatis (OR: 0.03, 95% CI: 0.00-0.20, p<0.001). This association was also shown to be significant in the adjusted analysis (OR: 0.08, 95% CI: 0.01-0.63, p=0.020). Having been previously treated for STIs also reduced the risk for C. trachomatis infection, both in the unadjusted and adjusted analysis (OR: 0.19, 95% CI: 0.04-0.54, p=0.006, and OR: 0.16, 95% CI: 0.03-0.51, p=0.006, respectively). In the unadjusted analysis, cohabiting with a partner also reduced the risk of getting infected with C. trachomatis (OR: 0.32, 95% CI: 0.12-0.76, p=0.015) (Table 3).


## 3.5. Risk Factors forN. gonorrhoeae Infection

The following factors were associated with the increased risk of acquiringN. gonorrhoeae infection: not knowing their partner’s HIV status, partner having other partners, engaging in intravaginal practices, and being C. trachomatis positive (Table 4).Table 4
Risk factors forN. gonorrhoeae infection.
FactorUnadjusted analysisOdds ratio with 95% confidence intervalsFull adjusted analysisOdds ratio with 95% confidence intervalsBackstep analysisOdds ratio with 95% confidence intervalsAge0.89 (0.81-0.96,p=0.007)0.84 (0.72-0.95,p=0.011)0.89 (0.80-0.98,p=0.023)Being employed0.99 (0.27-2.93,p=0.990)1.58 (0.30-7.22,p=0.566)—Married yes0.97 (0.15-3.62,p=990)2.09 (0.16-21.64,p=0.544)—Having an HIV-positive partner1.02 (0.26-4.18,p=0.978)1.80 (0.38-9.51,p=0.463)1.79 (0.41-8.78,p=0.445)Not knowing partner’s HIV status4.75 (1.38-18.74,p=0.016)6.72 (1.44-37.95,p=0.019)5.73(1.35-28.71,p=0.022)Cohabiting with partner0.49 (0.13-1.42,p=0.218)1.33 (0.23-6.68,p=0.734)—Age of 1st sex, 15-20 yrs0.46 (0.08-8.81,p=0.478)1.05 (0.11-28.79,p=0.971)—Age of 1st sex, 21+ yrs0.31 (0.04-6.64,p=0.333)1.80 (0.09-70.09,p=0.715)—Having 2-4 lifetime number of sex partners1.73 (0.50-7.94,p=0.417)1.65 (0.37-9.34,p=0.531)—Having >4 lifetime sex partners1.69 (0.36-8.78,p=0.499)1.65 (0.23-12.77,p=0.616)—Partner does not have other partners0.24 (0.01-1.37,p=0.184)0.11 (0.00-1.13,p=0.114)0.14 (0.01-1.07,p=0.106)Partner has other partners2.37 (0.82-6.96,p=0.107)3.67 (0.95-15.58,p=0.064)3.91 (1.13-14.65,p=0.034)Used a condom during last0.43 (0.10-1.36,p=0.193)0.47 (0.08-1.97,p=0.338)—Having a partner who is circumcised2.14 (0.67-9.46,p=0.242)1.29 (0.28-7.77,p=0.762)—Trimester pregnancy 2nd0.29 (0.06-1.56,p=0.123)0.15 (0.02-1.12,p=0.059)0.16 (0.03-1.03,p=0.045)Trimester pregnancy 3rd0.35 (0.10-1.66,p=0.134)0.14 (0.02-0.90,p=0.030)0.13 (0.02-0.76,p=0.016)Having been previously treated for STIs0.89 (0.27-2.50,p=0.828)2.33 (0.55-9.84,p=0.239)—Engages in intravaginal practices2.35 (0.35-9.16,p=0.279)5.10 (0.61-32.40,p=0.093)5.83 (0.76-31.51,p=0.052)Perceived one’s self at risk for STIs1.44 (0.51-4.66,p=0.504)1.29 (0.33-5.74,p=0.726)—Being C. trachomatis positive6.52 (2.22-18.49,p<0.001)7.95 (1.90-36.62,p=0.005)6.09 (1.73-22.03,p=0.005)In the unadjusted analysis, not knowing their partner’s HIV status increased the risk for infection by 4-fold (OR: 4.75, 95% CI: 1.38-28.71,p=0.016). Similarly, in the adjusted analysis, not knowing their partner’s HIV status increased the risk for infection by 5-fold (OR: 5.73, 95% CI: 1.35-28.71, p=0.022), and this was significant. In the adjusted analysis, women who reported that their partner had other partners had a close to 4-fold increased risk of getting infected, and this was significant (OR: 3.91, 95% CI: 1.13-14.65, p=0.034). Engaging in intravaginal practices increased the risk of infection by 5-fold (OR: 5.83, 95% CI: 0.76-31.51, p=0.052) in the adjusted analysis. Testing positive for C. trachomatis increased the risk for N. gonorrhoeae infection by 6-fold in the unadjusted analysis (OR: 6.52, 95% CI: 2.22-18.49, p<0.001). Similarly, in the adjusted analysis, the risk for N. gonorrhoeae infection in women who tested positive C. trachomatis increased by 6-fold (OR: 6.09, 95% CI: 1.73-22.03, p=0.005), and this association was significant. However, in the adjusted analysis, being in the second and third trimesters of pregnancy reduced the risk of getting infected with N. gonorrhoeae (odds ratio (OR): 0.16, 95% confidence interval (95% CI): 0.03-1.03, p=0.045, and OR: 0.13, 95% CI: 0.02-0.76, p=0.016, respectively) Table 4).


## 4. Discussion

In this study, the prevalence of investigated STIs was as follows:C. trachomatis, 12.2%, and N. gonorrhoeae, 4.1%. The majority of the samples were low positives for both pathogens. This is expected since these pathogens are cervical pathogens, and the sample analyzed was from the vagina which has a lower abundance of C. trachomatis and N. gonorrhoeae. In the current study of the women who tested positive for C. trachomatis, 14.9% tested positive for N. gonorrhoeae, and of the women who tested positive for N. gonorrhoeae, 43.8% tested for C. trachomatis (p<0.001). A study conducted among HIV-infected and HIV-uninfected pregnant women showed a C. trachomatis/N. gonorrhoeae coinfection rate of 7% in HIV-infected women [10]. Similarly, in a study by Smullin et al., a C. trachomatis/N. gonorrhoeae coinfection of 5.4% was reported for HIV-infected women [24], and a study by Nyemba et al. reported a coinfection rate of 7.7% for C. trachomatis/N. gonorrhoeae in HIV-infected women [25]. Coinfection with HIV and C. trachomatis/N. gonorrhoeae has been reported to be associated with risk of mother-to-child transmission of HIV [7]. Similarly, Reda et al. reported that there are clear connections between HIV transmission and infection with chlamydia and gonococcus [26]. Furthermore, several studies have reported that pregnant women with STIs have twice risk of giving birth to an HIV-infected infant, particularly in women with two STIs [7, 15, 27].Of the women who perceived themselves for not being at risk for contracting STIs, 48.3% tested positive for at least one STI. This study highlighted that a woman’s perceived risk and her actual risk may differ. This study identified risk factors associated with STI acquisition with the majority of the factors being linked to the women’s as well as their partners’ behavior. Therefore, in order to implement behavioral interventions to reduce HIV/STI risk, we will need to take into consideration the woman’s and her partner’s sexual behavior patterns. This can be facilitated using interventions targeting couples.The prevalence estimates forC. trachomatis among HIV-infected pregnant women range from 6.5% to 36.8% in South Africa. The prevalence of C. trachomatis infection in the current study was 12.2%. Studies conducted in Tshwane District in South Africa among HIV-infected pregnant women reported the prevalence of C. trachomatis infections to be between 17% and 36.8% [13, 22, 27–29]. Studies conducted in Cape Town, South Africa, among HIV-infected pregnant women reported that the prevalence of C. trachomatis was 6.5% and 20%, respectively [10, 24]. Similarly, another South African study, conducted among HIV-infected and uninfected pregnant women, reported a C. trachomatis prevalence of 15.3% in the HIV-infected and 14.3% in the HIV-uninfected women [25].The prevalence estimates forN. gonorrhoeae infection among HIV-infected pregnant women range from 0% to 6.9% in South Africa. In the current study, the prevalence of N. gonorrhoeae infection was 4.1%. Studies conducted in Tshwane District in South Africa among HIV-infected pregnant women reported the prevalence of N. gonorrhoeae infections to be between 0.9% and 6.9% [13, 22, 27–29]. Studies conducted in Cape Town, South Africa, among HIV-infected and uninfected pregnant women reported N. gonorrhoeae prevalence rates of 1.1% and 10%, respectively [10, 24]. In a study conducted in KwaZulu-Natal, South Africa, among pregnant women, a prevalence of 6.4% was reported for N. gonorrhoeae [30].The differences in prevalence estimates observed forC. trachomatis and N. gonorrhoeae between the current study and other studies may be due to different sensitivities of detection methods used, specimen types collected, study sample sizes, behavioral, sociodemographic factors, and clinical characteristics [31]. Furthermore, studies have found that the rate of infection persistence differs between pregnant and nonpregnant women, possibly due to differences in immune response caused by hormonal regulation. Pregnant women are more vulnerable to certain infections and in some cases suffer more severe consequences than nonpregnant women [32]. While there are several studies on the physiological changes during pregnancy and postpartum periods which increase HIV risk, factors that increase risky sexual behavior during pregnancy, consequently increasing the risk of HIV and STI acquisition and transmission, are not well described [33].Numerous demographic and behavioral factors have been reported to be associated withC. trachomatis and N. gonorrhoeae infections during pregnancy [22]. In pregnant women, younger age, low socioeconomic status, multiple sex partners, being unmarried, condomless sex, not knowing their partner’s HIV status, alcohol consumption, unemployment, low education attainment, physical violence, and psychological distress have been associated with C. trachomatis and N. gonorrhoeae infections [5, 12, 22, 23, 25, 27, 34].In this study, younger age was significantly associated with testing positive forC. trachomatis. It has been demonstrated by several studies that young age is a risk predictor for STIs [22, 27]. There are several biological, immunological, and behavioral factors, which contribute to STI acquisition [27], such as immature ectopic tissues on the cervix and sexual behavior which contribute to the growth of this pathogen [35]. Having sex at an early age was also associated with testing positive for C. trachomatis in the study. This finding is similar to findings published in other studies [11]. In this study, being unmarried was associated with testing positive for C. trachomatis. Similarly, a study conducted by Davey et al. in a population of pregnant women, it was observed that being unmarried was associated with being diagnosed with an STI, and the most prevalent STI in that population was C. trachomatis [10]. A systematic review conducted by Morris et al. confirmed that partner medical circumcision reduces women’s risk for T. vaginalis, bacterial vaginosis, and possibly genital ulcer disease [36]. However, for herpes simplex virus type 2, C. trachomatis, Treponema pallidum, and HIV, the evidence was mixed [36]. The current study did not find a protective effect of circumcision in terms of C. trachomatis acquisition. In the adjusted analysis conducted in this study, it was shown that having a circumcised partner increased the risk for infection by 3-fold (OR: 3.86, 95% CI: 1.21-17.27, p=0.039).TheC. trachomatis/N. gonorrhoeae coinfection rate was 14.9% in the studied population. According to Leonard et al., an estimated 10–40% of individuals with N. gonorrhoeae infection are concomitantly infected with C. trachomatis [37]. In addition, according to the adjusted analysis, the risk for C. trachomatis infection in women who tested positive for N. gonorrhoeae was 9-fold (OR: 9.16, 95% CI: 2.19-40.18, p=0.003). Coinfections of these two STIs may increase the susceptibility to long-term complications and transmissibility of these infections [38]. Additionally, N. gonorrhoeae shedding was higher in women with concurrent C. trachomatis infection than in those infected with N. gonorrhoeae only [39].Perceiving one’s self to be at risk for infection was shown to increase the risk for infection by 2-fold in the adjusted analysis conducted in this study (OR: 2.85, 95% CI: 1.16-7.68,p=0.028). Similarly, a study conducted by Gravningen et al. reported an increase in C. trachomatis prevalent infections with increasing risk perception [40]. According to Clifton et al., understanding the individuals’ need to access STI care services for the testing and treatment of infections, including the individuals’ risk perception for getting infected, is critical for STI control [41].Similar toC. trachomatis, in this study, younger age was significantly associated with testing positive for N. gonorrhoeae. A similar finding was reported by Connolly et al., where younger age was significantly associated (p=0.01) with the risk for N. gonorrhoeae infection [42]. Having an HIV-positive partner was significantly associated with having a prevalent N. gonorrhoeae infection. A study conducted by Davey et al. found that women who reported being in a concordant HIV-positive partnership had over twice the odds of having an STI. In that same study, 37% of women did not know their partner’s HIV serostatus [10]. In this study, not knowing their partners HIV status increased the risk for infection by 5-fold (OR: 5.73, 95% CI: 1.35-28.71, p=0.022).In this study, testing positive forC. trachomatis increased the risk for N. gonorrhoeae infection by 6-fold (OR: 6.09, 95% CI: 1.73-22.03, p=0.005). A study conducted by Jongen et al. found that having a prevalent C. trachomatis infection increased the risk of an incident N. gonorrhoeae infection [43]. In the adjusted analysis, women who reported that their partner had other partners had a 3-fold increased risk of getting infected with N. gonorrhoeae (OR: 3.91, 95% CI: 1.13-14.65, p=0.034). However, a study conducted by Gaffoor et al. reported that perceived male partner concurrency was not found to be significantly associated with incident STIs [44]. A later study conducted by Abbai et al. found that having a partner that has other partners was significantly associated with bacterial vaginosis infection [45].


## 5. Conclusion

This study showed a high prevalence ofC. trachomatis and N. gonorrhoeae single and coinfections in HIV-infected pregnant women residing in South Africa. A large proportion of these women were asymptomatic for infection. The highly asymptomatic nature of these STIs pose a treatment challenge since South Africa uses the syndromic management approach. To date, this approach is ineffective in controlling STIs and should be replaced by test and treat programmes. Cost effective point of care (POC) tests should be evaluated for implementation in resource limited settings. Future studies are urgently required to investigate the impact of C. trachomatis/N. gonorrhoeae coinfections in HIV-pregnant women since this data is lacking in our setting.The limitations of the study are as follow: participants were recruited from a single clinic and were not representative of the general population. Data was self-reported, and biases could have been introduced. The study only investigated the point prevalence of STIs and did not prospectively follow-up women through pregnancy to investigate incident infections or pregnancy outcomes. The strength of this study is that it fills a gap in the literature on the prevalence ofC. trachomatis and N. gonorrhoeae infection among HIV-infected pregnant women in Durban, South Africa, as well as identified the risk factors associated with these pathogens.



---

*Source: 7930567-2022-06-17.xml*